These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26095852)

  • 1. Development of novel hepatitis B virus capsid inhibitor using in silico screening.
    Hayakawa M; Umeyama H; Iwadate M; Tanahashi T; Yano Y; Enomoto M; Tamori A; Kawada N; Murakami Y
    Biochem Biophys Res Commun; 2015 Aug; 463(4):1165-75. PubMed ID: 26095852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.
    Mani N; Cole AG; Phelps JR; Ardzinski A; Cobarrubias KD; Cuconati A; Dorsey BD; Evangelista E; Fan K; Guo F; Guo H; Guo JT; Harasym TO; Kadhim S; Kultgen SG; Lee ACH; Li AHL; Long Q; Majeski SA; Mao R; McClintock KD; Reid SP; Rijnbrand R; Snead NM; Micolochick Steuer HM; Stever K; Tang S; Wang X; Zhao Q; Sofia MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovering novel direct acting antiviral agents for HBV using in silico screening.
    Murakami Y; Hayakawa M; Yano Y; Tanahashi T; Enomoto M; Tamori A; Kawada N; Iwadate M; Umeyama H
    Biochem Biophys Res Commun; 2015 Jan; 456(1):20-8. PubMed ID: 25446116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.
    Feld JJ; Colledge D; Sozzi V; Edwards R; Littlejohn M; Locarnini SA
    Antiviral Res; 2007 Nov; 76(2):168-77. PubMed ID: 17709147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes.
    Cui XJ; Cho YK; Song BC
    J Med Virol; 2015 Apr; 87(4):601-8. PubMed ID: 25612255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
    Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
    Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel compound Z060228 inhibits assembly of the HBV capsid.
    Guan H; Zhao G; Chen W; Wu G; Liu H; Jiang X; Li S; Wang LL
    Life Sci; 2015 Jul; 133():1-7. PubMed ID: 25921762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.
    Stray SJ; Johnson JM; Kopek BG; Zlotnick A
    Nat Biotechnol; 2006 Mar; 24(3):358-62. PubMed ID: 16474383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity.
    Butz K; Denk C; Fitscher B; Crnkovic-Mertens I; Ullmann A; Schröder CH; Hoppe-Seyler F
    Oncogene; 2001 Oct; 20(45):6579-86. PubMed ID: 11641783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery.
    Morgnanesi D; Heinrichs EJ; Mele AR; Wilkinson S; Zhou S; Kulp JL
    Antiviral Res; 2015 Nov; 123():204-15. PubMed ID: 26477294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.
    Glebe D; Geipel A
    Intervirology; 2014; 57(3-4):225-31. PubMed ID: 25034492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.
    Wang YJ; Lu D; Xu YB; Xing WQ; Tong XK; Wang GF; Feng CL; He PL; Yang L; Tang W; Hu YH; Zuo JP
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7061-72. PubMed ID: 26349829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.